Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Signaturefd LLC

Signaturefd LLC trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW) by 19.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,685 shares of the medical research company’s stock after selling 1,652 shares during the period. Signaturefd LLC’s holdings in Edwards Lifesciences were worth $510,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in EW. SG Americas Securities LLC grew its stake in Edwards Lifesciences by 4.9% in the 3rd quarter. SG Americas Securities LLC now owns 37,480 shares of the medical research company’s stock valued at $2,597,000 after acquiring an additional 1,734 shares during the last quarter. Caprock Group LLC boosted its stake in shares of Edwards Lifesciences by 4.8% during the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock worth $597,000 after purchasing an additional 392 shares during the last quarter. Oak Thistle LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $700,000. Czech National Bank boosted its stake in shares of Edwards Lifesciences by 48.1% during the 3rd quarter. Czech National Bank now owns 106,252 shares of the medical research company’s stock worth $7,361,000 after purchasing an additional 34,487 shares during the last quarter. Finally, Asset Management One Co. Ltd. boosted its stake in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company’s stock worth $22,393,000 after purchasing an additional 1,622 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 1.0 %

NYSE EW opened at $88.62 on Thursday. The company’s fifty day simple moving average is $90.23 and its 200-day simple moving average is $78.69. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock has a market cap of $53.34 billion, a P/E ratio of 38.53, a PEG ratio of 4.31 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the company posted $0.64 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Equities research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Evercore ISI raised their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Oppenheimer raised their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Finally, Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price for the company in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.